0
Login

Novocure Ltd

instructor-image Bradford Hall

0

... En
... Certificate Company
... 0 Investors
... 00h 00m
NVCR logo
Novocure Ltd
NVCR Health Care
$16.31 ▼ -4.23%
$0.72 today · as of 29 Jul 2026
49 S.I.F.T
S.I.F.T.™ Analysis
Red
Login to Issue Journal
Caution – significant pillar weakness detected.
Last updated: 29 Jul 2026 · Confidence: 55%
Pillar Breakdown
🛡 Safety 35
Balance sheet or moat concerns are weighing on the score.
💰 Income 35
High cyclicality and lack of recurring revenue are limiting stability.
📊 Fundamentals 35
Strong growth but valuation is elevated.
⏱ Time 65
Shorter track record or weaker tailwinds.
🧠 Munger Reality Filter AVOID

No meaningful moat; negative ROE and weak fundamentals indicate poor competitive positioning.

Strengths: Moderate time-in-market score of 65
Risks: Negative ROE of -1.97 signals ongoing losses, Extremely high debt-to-CFO ratio of 56.21, Zero warchest and dividend yield with low safety/income scores
📈 Price History

Business Overview

Key Metrics
ROE (10yr)
-2.0%
Debt / CFO
N/A
Div. Yield
0.00%
FCF Growth
0.0%

FAQ

Financial Details

Recent Quarters
Quarter Revenue Gross Profit EPS
No quarterly data available.
Segment Breakdown
Data Center 56%
Client 28%
Gaming 9%
Embedded 7%

Management

Leadership Summary
  • Experienced team with deep expertise in oncology and medtech commercialization
  • Strong emphasis on clinical evidence generation and regulatory approvals
  • Focus on global market expansion particularly in Europe and Asia
  • Leadership has navigated multiple funding rounds and IPO successfully
Track Record

Led Novocure from startup to public company with approved therapies in glioblastoma and mesothelioma; achieved multiple FDA and CE mark clearances.

Recent Commentary

“In 2023 earnings calls, management highlighted pipeline progress in lung cancer and pancreatic cancer trials while addressing reimbursement challenges.”

Analyst Reviews & Risks

Wall Street Consensus
4.6
out of 5 (Strong Buy)
Average Target: $485.00
Key Investment Risks
  • Negative ROE of -1.97 signals ongoing losses
  • Extremely high debt-to-CFO ratio of 56.21
  • Zero warchest and dividend yield with low safety/income scores
Ownership & Sentiment

Institutional Ownership: N/A%

Short Interest: N/A%

AI Investment Thesis
  • Novocure's Tumor Treating Fields (TTFields) technology offers a novel, non-invasive cancer treatment with proven survival benefits in glioblastoma multiforme (GBM).
  • Robust intellectual property portfolio creates a strong competitive moat and licensing potential.
  • Pipeline expansion into high-unmet-need indications like non-small cell lung cancer and ovarian cancer unlocks multi-billion-dollar market opportunities.
  • Improving reimbursement coverage and rising physician adoption support durable revenue growth and margin expansion.
  • Strategic optionality exists for partnerships, geographic expansion, or M&A as clinical data matures.
Key Catalysts & Risks
Catalysts
  • Positive Phase 3 LUNAR trial readout in NSCLC
  • FDA approval or label expansion for new indications
  • Accelerated revenue growth from Optune Gio adoption
  • New reimbursement wins in Europe and Japan
Risks
  • Heavy reliance on GBM revenue with limited current diversification
  • Clinical or regulatory setbacks in ongoing pivotal trials
  • Reimbursement or pricing pressure in key markets
  • Competition from established oncology therapies and new modalities
  • Prolonged cash burn and path to sustained profitability
Peer Comparison
Company P/E Rev Growth Gross Margin ROE Debt/Equity
NVDA N/A N/A% N/A% 61.51% 0.51
INTC N/A N/A% N/A% -5.53% 6.65
AVGO N/A N/A% N/A% 16.36% 2.72
AMD N/A N/A% N/A% 6.29% 1.78
  • ...

    Investors

     0

  • Ticker

     NVCR
  • ...

    Sector

     Health Care

  • Current Price

     $16.31

  • S.I.F.T. Score

     49
Login to Add Portfolio